Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Fill Frankos' Shoes As Major Dietary Supplement Initiatives Pend

This article was originally published in The Tan Sheet

Executive Summary

The successor to Vasilios "Bill" Frankos, FDA's director of Dietary Supplement Programs, will face a full plate of imminent and ongoing regulatory issues
Advertisement

Related Content

Supplement Firms Have ‘Continuous Monitoring’ Burden To Show Product Safety
Supplement Firms Have ‘Continuous Monitoring’ Burden To Show Product Safety
FDA Interim Supplement Chief Spiller Has Deputy Commissioner Experience
GAO New Dietary Ingredient Probe Has Puzzled Firms Seeking Legal Advice
Herbalife Hires FDA's Frankos For Compliance/Safety Position
Herbalife Hires FDA's Frankos For Compliance/Safety Position
Prevention Advocate Taylor Named FDA Deputy Commissioner For Foods
Senate Exempts Supplements From Redundant Regs, Suppliers Left Hanging
People In Brief
NDI Notification Guidance To Assist Puzzled Industry Could Emerge In 2009

Topics

Advertisement
UsernamePublicRestriction

Register

PS103721

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel